NZ620887A - A novel formulation of diclofenac - Google Patents

A novel formulation of diclofenac

Info

Publication number
NZ620887A
NZ620887A NZ620887A NZ62088710A NZ620887A NZ 620887 A NZ620887 A NZ 620887A NZ 620887 A NZ620887 A NZ 620887A NZ 62088710 A NZ62088710 A NZ 62088710A NZ 620887 A NZ620887 A NZ 620887A
Authority
NZ
New Zealand
Prior art keywords
diclofenac
sodium lauryl
unit dose
diclofenac acid
acid
Prior art date
Application number
NZ620887A
Other languages
English (en)
Inventor
Felix Meiser
Marck Norret
Aaron Dodd
H William Bosch
Adrian Russell
Original Assignee
Iceutica Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43010610&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ620887(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2009901748A external-priority patent/AU2009901748A0/en
Application filed by Iceutica Pty Ltd filed Critical Iceutica Pty Ltd
Priority to NZ710383A priority Critical patent/NZ710383A/en
Publication of NZ620887A publication Critical patent/NZ620887A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
NZ620887A 2009-04-24 2010-04-23 A novel formulation of diclofenac NZ620887A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ710383A NZ710383A (en) 2009-04-24 2010-04-23 A novel formulation of diclofenac

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17229109P 2009-04-24 2009-04-24
AU2009901748A AU2009901748A0 (en) 2009-04-24 A Novel Formulation of Diclofenac
NZ595987A NZ595987A (en) 2009-04-24 2010-04-23 A novel formulation of diclofenac

Publications (1)

Publication Number Publication Date
NZ620887A true NZ620887A (en) 2015-08-28

Family

ID=43010610

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ620887A NZ620887A (en) 2009-04-24 2010-04-23 A novel formulation of diclofenac
NZ710383A NZ710383A (en) 2009-04-24 2010-04-23 A novel formulation of diclofenac
NZ595987A NZ595987A (en) 2009-04-24 2010-04-23 A novel formulation of diclofenac

Family Applications After (2)

Application Number Title Priority Date Filing Date
NZ710383A NZ710383A (en) 2009-04-24 2010-04-23 A novel formulation of diclofenac
NZ595987A NZ595987A (en) 2009-04-24 2010-04-23 A novel formulation of diclofenac

Country Status (23)

Country Link
US (12) US8735450B2 (https=)
EP (2) EP3290030A1 (https=)
JP (2) JP6222924B2 (https=)
KR (5) KR20170002683A (https=)
CN (5) CN106727424A (https=)
AP (2) AP2015008933A0 (https=)
AU (1) AU2010239080B2 (https=)
CA (1) CA2759123C (https=)
CO (1) CO6470810A2 (https=)
DK (1) DK2421525T3 (https=)
EA (1) EA201171285A1 (https=)
HK (2) HK1202061A1 (https=)
IL (1) IL215869B (https=)
MA (1) MA33295B1 (https=)
MX (2) MX347290B (https=)
MY (1) MY168079A (https=)
NZ (3) NZ620887A (https=)
PH (1) PH12015500301B1 (https=)
SG (2) SG175314A1 (https=)
TN (1) TN2011000543A1 (https=)
UA (1) UA106232C2 (https=)
WO (1) WO2010121327A1 (https=)
ZA (1) ZA201108650B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2054042T3 (da) 2006-06-30 2020-08-03 Iceutica Pty Ltd Fremgangsmåder til fremstilling af biologisk aktive forbindelser i nanopartikelform
AU2010239081C1 (en) 2009-04-24 2014-11-06 Iceutica Pty Ltd A novel formulation of indomethacin
JP6222924B2 (ja) 2009-04-24 2017-11-01 イシューティカ ピーティーワイ リミテッド ジクロフェナクの新規製剤
AU2010239160B2 (en) * 2009-04-24 2014-10-02 Iceutica Pty Ltd Method for improving the dissolution profile of a biologically active material
SG10201401705VA (en) * 2009-04-24 2014-08-28 Iceutica Pty Ltd Production of encapsulated nanoparticles at commercial scale
JP5909796B2 (ja) * 2012-03-02 2016-04-27 株式会社サンギ 難溶性物質の水溶解性改善方法
WO2014060856A1 (en) * 2012-10-16 2014-04-24 Wockhardt Limited Pharmaceutical compositions of diclofenac or salts thereof
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
MX2015013247A (es) * 2013-03-15 2016-11-25 Iceutica Inc Formulacion de acetato de abiraterona.
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
MX2017015699A (es) * 2015-06-05 2018-12-11 Lupin Ltd Composiciones de acido diclofenaco.
WO2017136617A1 (en) 2016-02-04 2017-08-10 Cinrx Pharma, Llc Deuterated domperidone compositions and methods for therapy of disorders
US11364226B2 (en) 2017-06-30 2022-06-21 Cinrx Pharma, Llc Deuterated domperidone compositions, methods, and preparation
CN106267209A (zh) * 2016-07-18 2017-01-04 苏州朗易生物医药研究有限公司 低剂量非甾体抗炎类药物组合物及其制备工艺
CA3181327A1 (en) 2016-11-10 2018-05-17 Medisca Pharmaceutique Inc. Pharmaceutical compounding methods and systems
CN106580886A (zh) * 2016-12-05 2017-04-26 北京万全德众医药生物技术有限公司 一种双氯芬酸钾散剂及其制备方法
KR102771163B1 (ko) 2017-04-07 2025-02-25 엠에이에이 래보러토리스, 인코포레이티드 치료제의 용해도 및 생체이용률을 향상시키는 방법
US12478612B2 (en) 2017-06-30 2025-11-25 Cindome Pharma, Inc. Deuterated domperidone compositions, methods, and preparation
WO2019030773A1 (en) * 2017-08-10 2019-02-14 Sarudbhava Formulations Private Limited DICLOFENAC COMPOSITIONS WITH LOW DOSE
KR20220007198A (ko) 2020-07-10 2022-01-18 오훈 골프장의 홀컵 교체를 위한 홀 가공장치 및 그 홀의 시공방법
CN114088624B (zh) * 2021-11-09 2022-08-26 北京中检葆泰生物技术有限公司 用于谷物颗粒表面规则度检测设备
CN115317464B (zh) * 2022-09-01 2023-08-08 苏州弘森药业股份有限公司 一种双氯芬酸钾微胶囊及其制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2642486B2 (ja) 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
NZ248813A (en) 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
US5500331A (en) 1994-05-25 1996-03-19 Eastman Kodak Company Comminution with small particle milling media
US5478705A (en) 1994-05-25 1995-12-26 Eastman Kodak Company Milling a compound useful in imaging elements using polymeric milling media
US5518738A (en) 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
IE80467B1 (en) 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
IT1286778B1 (it) * 1996-11-20 1998-07-17 Alfa Wassermann Spa Capsule contenenti diclofenac o suoi sali in soluzione
WO1998047499A1 (en) * 1997-04-22 1998-10-29 Nippon Kayaku Kabushiki Kaisha Flutamide preparations and method for manufacturing the same
US6375986B1 (en) 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
EP1313451B1 (en) 2000-08-31 2009-03-11 Jagotec AG Milled particles
AU2002334939A1 (en) 2001-10-12 2003-04-22 Eugene R. Cooper Compositions having a combination of particles for immediate release and for controlled release
US7101576B2 (en) 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
GB0320522D0 (en) 2003-09-02 2003-10-01 Glaxo Group Ltd Formulation
UA89513C2 (uk) 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
CA2590675A1 (en) 2004-12-15 2006-06-22 Elan Pharma International Ltd. Nanoparticulate tacrolimus formulations
CN101094659A (zh) 2004-12-31 2007-12-26 伊休蒂卡有限公司 纳米微粒组合物及其合成方法
US20060204588A1 (en) 2005-03-10 2006-09-14 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
MX2007013467A (es) 2005-04-28 2008-01-21 Wyeth Corp Tanaproget micronizado y composiciones que contienen el mismo.
JO3352B1 (ar) * 2005-06-17 2019-03-13 Apr Applied Pharma Res Sa صيغ دايكلوفيناك وطرق استخدامه
ES2334164T3 (es) * 2005-12-15 2010-03-05 Acusphere, Inc. Procedimiento de preparacion de formulaciones farmaceuticas a base de particulas para administracion parenteral.
WO2007070851A2 (en) * 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
DK2054042T3 (da) * 2006-06-30 2020-08-03 Iceutica Pty Ltd Fremgangsmåder til fremstilling af biologisk aktive forbindelser i nanopartikelform
BRPI0713053A2 (pt) 2006-06-30 2012-07-17 Iceutica Pty Ltd métodos para a preparação de compostos biologicamente ativos na forma nanoparticulada
JP6222924B2 (ja) 2009-04-24 2017-11-01 イシューティカ ピーティーワイ リミテッド ジクロフェナクの新規製剤

Also Published As

Publication number Publication date
KR20170002683A (ko) 2017-01-06
AP2015008933A0 (en) 2015-12-31
US20150150805A1 (en) 2015-06-04
US9017721B2 (en) 2015-04-28
BRPI1014272A2 (pt) 2016-10-18
US9173854B2 (en) 2015-11-03
US20170100356A1 (en) 2017-04-13
KR20140124873A (ko) 2014-10-27
EP3290030A1 (en) 2018-03-07
TN2011000543A1 (en) 2013-05-24
AP2011005989A0 (en) 2011-12-31
CN106727477A (zh) 2017-05-31
CN102438610A (zh) 2012-05-02
EP2421525A1 (en) 2012-02-29
UA106232C2 (uk) 2014-08-11
PH12015500301A1 (en) 2015-12-07
CA2759123A1 (en) 2010-10-28
US9180095B2 (en) 2015-11-10
CN106420667A (zh) 2017-02-22
JP6222924B2 (ja) 2017-11-01
HK1202061A1 (en) 2015-09-18
NZ595987A (en) 2014-02-28
US20180296514A1 (en) 2018-10-18
EP2421525A4 (en) 2013-01-23
MX337619B (es) 2016-03-10
JP2012524723A (ja) 2012-10-18
US20160067199A1 (en) 2016-03-10
US8999387B2 (en) 2015-04-07
CA2759123C (en) 2019-01-15
CN104161743A (zh) 2014-11-26
US20140220121A1 (en) 2014-08-07
US9186328B2 (en) 2015-11-17
AU2010239080B2 (en) 2014-08-28
JP2015157851A (ja) 2015-09-03
US20150157573A1 (en) 2015-06-11
KR101580656B1 (ko) 2015-12-30
US20120135047A1 (en) 2012-05-31
CN106727424A (zh) 2017-05-31
US20130209569A1 (en) 2013-08-15
US8679544B2 (en) 2014-03-25
EP2421525B1 (en) 2017-06-07
US20150150824A1 (en) 2015-06-04
JP6154846B2 (ja) 2017-06-28
KR20120029398A (ko) 2012-03-26
IL215869A0 (en) 2012-01-31
KR20150086563A (ko) 2015-07-28
DK2421525T3 (en) 2017-09-25
US8735450B2 (en) 2014-05-27
KR20150018647A (ko) 2015-02-23
MX347290B (es) 2017-04-17
SG175314A1 (en) 2011-11-28
CO6470810A2 (es) 2012-06-29
EA201171285A1 (ru) 2012-05-30
US20150150823A1 (en) 2015-06-04
WO2010121327A1 (en) 2010-10-28
MX2011011222A (es) 2012-02-08
US20140248359A1 (en) 2014-09-04
PH12015500301B1 (en) 2015-12-07
MA33295B1 (fr) 2012-05-02
AP3774A (en) 2016-08-31
NZ710383A (en) 2017-04-28
IL215869B (en) 2019-02-28
MY168079A (en) 2018-10-11
AU2010239080A1 (en) 2011-11-10
SG10201401700XA (en) 2014-06-27
HK1231383A1 (zh) 2017-12-22
ZA201108650B (en) 2013-01-30
US9180096B2 (en) 2015-11-10
US20160058707A1 (en) 2016-03-03

Similar Documents

Publication Publication Date Title
NZ620887A (en) A novel formulation of diclofenac
NZ620879A (en) A novel formulation of indomethacin
NZ626401A (en) A novel formulation of naproxen
NZ621802A (en) A novel formulation of meloxicam
WO2013022783A3 (en) Progesterone containing oral dosage forms and related methods
RU2005115855A (ru) Композиция трамадола продлонгированного высвобождением с 24-часовым действием
WO2013016697A3 (en) 17-hydroxyprogesterone ester-containing oral compositions and related methods
CA2941464C (en) Oral dosage form
CA2969860A1 (en) Compositions and methods for enhancing athletic performance
WO2009040069A3 (en) Use of bq-610 alone or in combination with helodermin as a therapeutic agent
JP6441825B2 (ja) フィラーの効能維持用組成物
BR9916361A (pt) Forma de dosagem de tabletes de liberação controlada, formulação de tablete de liberação controlada, composição granular para prensagem em uma forma de dosagem de tablete de liberação controlada, e, métodos para preparar uma composição granular, para preparar uma forma de dosagem de tabletes de liberação controlada de divalproex sódio e para tratar epilepsia
US20140363673A1 (en) Therapeutic agent for inflammatory bowel disease
JP2005528430A5 (https=)
JP5697668B2 (ja) 口腔内崩壊錠剤
JP6196847B2 (ja) 防已含有組成物
JP7017849B2 (ja) 経口投与剤形
JP2010506855A5 (https=)
WO2009000150A1 (fr) Utilisation de la sanchinoside dans le traitement de la septicémie
RS60172B1 (sr) Farmaceutska kompozicija u obliku oralne suspenzije, koja uključuje flavonoidnu frakciju i ksantan gumu
CN102600098A (zh) 一种氨基葡萄糖缓释制剂及其制备方法
JP2014214141A (ja) 防已含有組成物
ES2984013T3 (es) Composiciones de hidróxido de hierro férrico modificado con ligando carboxilato para su uso en el tratamiento o prevención de la deficiencia de hierro asociada con enfermedades hepáticas
JP2005154281A (ja) 関節障害予防及び治療用医薬組成物
JP2014221725A (ja) 防已含有組成物

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 23 APR 2017 BY WRAYS

Effective date: 20160301

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 APR 2018 BY WRAYS

Effective date: 20170410

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 APR 2019 BY WRAYS

Effective date: 20180410

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 APR 2020 BY WRAYS PTY LTD

Effective date: 20190410

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 APR 2021 BY WRAYS PTY LTD

Effective date: 20200409

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 APR 2022 BY WRAYS PTY LTD

Effective date: 20210419

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 APR 2023 BY WRAYS PTY LTD

Effective date: 20220411

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 APR 2024 BY WRAYS PTY LTD

Effective date: 20230413

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 APR 2025 BY WRAYS PTY LTD

Effective date: 20240328

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 APR 2026 BY WRAYS PTY LTD

Effective date: 20250422